Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PepGen Inc.
The annual reimbursement price negotiations between pharma firms and China’s National Healthcare Security Administration are just around the corner. While some have chosen to walk away from the process completely, others including majors BeiGene and Hengrui are girding up for another round of potentially deep cuts.
AstraZeneca and Moderna also shone as the pharma, biotech and allied industries came together in London on 30 November to celebrate a year of exceptional achievement at the 18th Annual Scrip Awards, hosted by the actor, comedian and presenter Stephen Mangan.
Gilead and Arcus believe their ‘Fc silent’ TIGIT inhibitor candidate could be best in class, but analysts think only outstanding results in lung cancer will sway investor sentiment.
Much of the biopharma and other health-related industries in China were already feeling the chill from ongoing macro-economic and other headwinds this year, which now look set to be complicated further by the added strain of social unrest over strict COVID containment policies. The combination of factors is already prompting some to take steps towards restructuring and divestments to survive.
- Drug Delivery
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule